Stock comparison
Madrigal Pharmaceuticals
Thermo Fisher Scientific
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MDGL
Madrigal Pharmaceuticals
Market cap
$12.07B
Sector
Healthcare
TMO
Thermo Fisher Scientific
Market cap
$162.9B
Sector
Healthcare
Overall winner
Thermo Fisher Scientific TMO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MDGL | TMO | Winner |
|---|---|---|---|
| Warren Buffett | 26F | 52C | TMO |
| Benjamin Graham | 60D | 72B | TMO |
| Philip Fisher |
Side-by-side metrics
| Metric | MDGL | TMO |
|---|---|---|
| Market cap | $12.07B | $162.9B |
| P/E (TTM) | - | 23.8x |
| EV/EBIT | - | 25.0x |
| ROIC (TTM) | -35.2% | 7.33% |
| Gross margin | 93.07% | 39.41% |
| Net margin | -27.32% | 15.18% |
| Revenue CAGR 5y | - |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MDGL leads on
- EV/EBIT-vs 25.0x+162%
- P/E (TTM)-vs 23.8x+148%
- Gross margin93.07%vs 39.41%+58%
- Debt / Equity0.6xvs 0.8x
More like TMO
Related on invest-like
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.